Forget the breast implants, dermal fillers and eye-lash enlargers. Forget even the specialty pharmaceutical portfolio of genuine medical products. If you want to know where Allergan’s growth could come from over the next few years, look no further than its treatment for chronic migraines.
That would be Botox. Yes, the Food & Drug Administration on Oct. 15 approved this well-known treatment for wrinkled skin to treat chronic migraines as well. It’s a market that could be worth anywhere between $250 million to $1 billion in annual sales, Cramer said. Allergan right now is also is testing Botox’s effect on overactive bladders, an indication which, FDA willing, could hit the market in 2012.
Cramer wanted to know more about Botox’s potential, so he invited CEO David Pyott onto “Mad Money.” Check out the video to see the full interview.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org